Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €114.35 EUR
Change Today +12.62 / 12.41%
Volume 270.0
As of 1:37 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

incyte corp (ICY) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/16/15 - €118.00
52 Week Low
10/13/14 - €34.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INCYTE CORP (ICY)

incyte corp (ICY) Related Businessweek News

No Related Businessweek News Found

incyte corp (ICY) Details

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, which is in Phase III clinical trial for pancreatic cancer; and in Phase II trial for the treatment of breast cancer, non-small cell lung cancer, and colorectal cancer, as well as INCB39110 that is in Phase I/II trial for malignancies; and in Phase II trial for non-small cell lung cancer. The company’s product pipeline also comprises INCB52793, which is in Phase I/II clinical trial for the treatment of B-lymphoid malignancies; INCB50465 that is in Phase I/II clinical trial for hematology/oncology; and INCB39110+INCB40093, which is in Phase I/II trial for B-lymphoid malignancies. In addition, it is developing epacadostat that is in Phase II clinical trial for metastatic melanoma, as well as in Phase I/II trial for non-small cell lung cancer and various tumor types; and capmatinib, which is in Phase I/II clinical trial for the treatment of solid tumors, as well as in Phase II trial for hepatocellular carcinoma and non-small cell lung cancer. Further, the company is developing INCB54828 that is in Phase I/II clinical trial for the treatment of solid tumors; INCB54329, which is in Phase I/II clinical trial for the treatment of hematology/oncology; and baricitinib that is in Phase III trial for rheumatoid arthritis, as well as in Phase IIb clinical trial for psoriasis, and Phase II trial for diabetic nephropathy. It has a collaboration and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

588 Employees
Last Reported Date: 02/17/15
Founded in 1991

incyte corp (ICY) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $2.9M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $113.8K
Chief Drug Development Officer and Executive ...
Total Annual Compensation: $403.0K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $365.6K
Executive Vice President of Human Resources
Total Annual Compensation: $354.0K
Compensation as of Fiscal Year 2014.

incyte corp (ICY) Key Developments

Eli Lilly and Company and Incyte Corporation Announce Positive Results of RA-BEGIN Study

Eli Lilly and Company and Incyte Corporation announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis (RA). The study met its primary objective of demonstrating non-inferiority of baricitinib monotherapy to methotrexate monotherapy based on ACR20 response rate after 24 weeks of treatment. Additionally, baricitinib was superior to methotrexate based on ACR20 response. The RA-BEGIN study included patients who had limited or no prior treatment with methotrexate, and were naïve to other conventional or biologic disease-modifying antirheumatic drugs (DMARDs). Part of a larger Phase 3 program of more than 3,000 RA patients at various points in the RA treatment continuum, RA-BEGIN enrolled nearly 600 patients who were randomized to one of the following treatment groups: Once-weekly oral methotrexate monotherapy; 4 mg once-daily oral baricitinib monotherapy; 4 mg once-daily oral baricitinib in combination with once-weekly oral methotrexate. In RA-BEGIN, the incidence of treatment-emergent adverse events and serious adverse events, including serious infections, was similar across treatment groups. No cases of tuberculosis or gastrointestinal perforation were reported during the study. The most common adverse events observed were consistent with previous studies of baricitinib in RA. Discontinuations due to adverse events were more common in patients receiving the combination of baricitinib plus methotrexate. A large majority of patients completing RA-BEGIN opted to participate in a long-term extension study.

Incyte Corporation Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 03:15 PM

Incyte Corporation Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 03:15 PM. Venue: Le Parker Meridien Hotel, New York, New York, United States. Speakers: Reid M. Huber, Chief Scientific Officer and Executive Vice President.

Aduro Biotech Enters into Clinical Trial Agreement with Incyte Corporation to Evaluate Combination of Two Novel Cancer Immunotherapies for the Treatment of Ovarian Cancer

Aduro Biotech, Inc. announced that it has entered into a clinical trial agreement with Incyte Corporation to evaluate the safety, tolerability and preliminary efficacy of Aduro's lead LADD immunotherapy, CRS-207, in combination with Incyte's oral indoleamine dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), in patients with ovarian cancer. The combination of both investigational immunotherapeutic agents, which have different but complementary mechanisms directed at enhancing the body's own immune defenses, may provide unique synergies in fighting cancer. Incyte's epacadostat has been shown in vitro and in preclinical tumor models to enhance activities of multiple types of immune cells by reducing the immune suppression characteristic of the tumor microenvironment. Aduro's CRS-207 has been shown to stimulate immune cell activity, with particular targeting mechanisms that seek and attack tumor cells that express mesothelin like those found in ovarian cancer. The Phase 1/2 trial, which is being funded equally between the two companies, is designed to test combinations of CRS-207 with two dose levels of epacadostat in dose escalation and then will expand to a Phase 2 evaluating the combination at the optimal dose level compared to CRS-207 alone based on safety and tumor biomarkers. The study plans to enroll up to 40 patients in Phase 1 and up to 86 patients in Phase 2 with platinum-resistant ovarian, fallopian or peritoneal cancers. The trial is expected to begin enrolling patients in early 2016. Under the terms of the collaboration, Aduro and Incyte will collaborate on a non-exclusive basis to evaluate the combination. Aduro will be responsible for conducting the study and the results will be used to determine whether further clinical development of this combination is warranted.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICY:GR €114.35 EUR +12.62

ICY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $60.48 USD +0.97
ARIAD Pharmaceuticals Inc $6.51 USD +0.63
BioMarin Pharmaceutical Inc $113.00 USD +3.21
Jazz Pharmaceuticals PLC $137.50 USD +5.05
Vertex Pharmaceuticals Inc $115.18 USD +7.95
View Industry Companies

Industry Analysis


Industry Average

Valuation ICY Industry Range
Price/Earnings 100.0x
Price/Sales 35.1x
Price/Book 413.0x
Price/Cash Flow 1,717.9x
TEV/Sales 33.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INCYTE CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at